Wedbush Reaffirms Outperform Rating for SpringWorks Therapeutics (NASDAQ:SWTX)

Wedbush reiterated their outperform rating on shares of SpringWorks Therapeutics (NASDAQ:SWTX) in a report published on Thursday morning,RTT News reports. They currently have a $81.00 target price on the stock. Wedbush also issued estimates for SpringWorks Therapeutics’ Q2 2025 earnings at ($0.68) EPS, Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($2.43) EPS, FY2026 earnings at $0.23 EPS, FY2027 earnings at $3.55 EPS and FY2028 earnings at $8.09 EPS.

SWTX has been the topic of several other research reports. HC Wainwright restated a “buy” rating and set a $74.00 target price on shares of SpringWorks Therapeutics in a research report on Wednesday, February 12th. Evercore ISI increased their price target on SpringWorks Therapeutics from $60.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, February 12th. Finally, Guggenheim reduced their price target on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $71.50.

SpringWorks Therapeutics Trading Up 7.5 %

Shares of SWTX stock opened at $59.93 on Thursday. The business’s 50 day simple moving average is $40.70 and its 200 day simple moving average is $37.47. SpringWorks Therapeutics has a one year low of $28.21 and a one year high of $62.00.

SpringWorks Therapeutics (NASDAQ:SWTX) last posted its quarterly earnings data on Thursday, February 20th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.38). SpringWorks Therapeutics had a negative net margin of 203.09% and a negative return on equity of 48.21%. As a group, equities analysts anticipate that SpringWorks Therapeutics will post -3.17 EPS for the current year.

Insider Transactions at SpringWorks Therapeutics

In other SpringWorks Therapeutics news, COO Badreddin Edris sold 20,000 shares of the company’s stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $41.97, for a total transaction of $839,400.00. Following the transaction, the chief operating officer now owns 209,600 shares in the company, valued at approximately $8,796,912. This represents a 8.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Daniel Lynch sold 175,000 shares of the firm’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $54.46, for a total transaction of $9,530,500.00. Following the completion of the transaction, the director now directly owns 130,944 shares in the company, valued at approximately $7,131,210.24. The trade was a 57.20 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 313,822 shares of company stock valued at $16,802,876 over the last ninety days. 7.61% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of SWTX. Creative Planning bought a new position in SpringWorks Therapeutics during the 3rd quarter valued at $254,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of SpringWorks Therapeutics by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,686 shares of the company’s stock valued at $87,000 after purchasing an additional 474 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of SpringWorks Therapeutics by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 14,285 shares of the company’s stock valued at $458,000 after purchasing an additional 5,582 shares in the last quarter. Principal Financial Group Inc. lifted its position in shares of SpringWorks Therapeutics by 102.5% during the third quarter. Principal Financial Group Inc. now owns 918,445 shares of the company’s stock valued at $29,427,000 after purchasing an additional 464,903 shares in the last quarter. Finally, Assetmark Inc. lifted its position in shares of SpringWorks Therapeutics by 13.7% during the 3rd quarter. Assetmark Inc. now owns 46,020 shares of the company’s stock worth $1,474,000 after buying an additional 5,546 shares in the last quarter.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.